Literature DB >> 14756852

Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation.

Anthony W Fox1.   

Abstract

OBJECTIVE: To quantitate onset of effect of all formulations of sumatriptan, and to investigate whether this is related to rate, not extent, of drug absorption.
METHODS: From published literature, for 4 formulations of sumatriptan and matching placebos, response rates were modeled using a simple logarithmic equation, with a being a parameter of curve convexity and B, a location parameter (equal to response rate at 2 hours [the standard regulatory parameter]). The average rate of drug absorption (A) was estimated by dividing the maximal drug concentration by the time needed to achieve it (Cmax/Tmax). Least mean square correlation was then performed between the therapeutic gains and therapeutic ratios of curve convexity and rate of drug absorption.
RESULTS: -Models closely fitted observed response rates (2 hours or less). Curve convexity correlated with rate of drug absorption. Sumatriptan response rates (0 to 2 hours) for formulations correlated with rate, not extent, of drug absorption. The range of rates of onset of effect among different routes of administration was greater than that for tablets with 4-fold differences in dose size.
CONCLUSION: Onset of effect is related to rate of absorption of sumatriptan. There is greater scope for improving onset of effect using an alternative route of administration than by increasing the oral dose.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14756852     DOI: 10.1111/j.1526-4610.2004.04030.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  8 in total

1.  The complex actions of sumatriptan on rat dural afferents.

Authors:  Andrea M Harriott; Nicole N Scheff; Michael S Gold
Journal:  Cephalalgia       Date:  2012-06-18       Impact factor: 6.292

2.  Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients.

Authors:  Anna Ferrari; Diego Pinetti; Alfio Bertolini; Ciro Coccia; Emilio Sternieri
Journal:  Eur J Clin Pharmacol       Date:  2008-01-08       Impact factor: 2.953

Review 3.  Why pharmacokinetic differences among oral triptans have little clinical importance: a comment.

Authors:  Anna Ferrari; Ilaria Tiraferri; Laura Neri; Emilio Sternieri
Journal:  J Headache Pain       Date:  2010-09-29       Impact factor: 7.277

Review 4.  Breath powered nasal delivery: a new route to rapid headache relief.

Authors:  Per G Djupesland; John C Messina; Ramy A Mahmoud
Journal:  Headache       Date:  2013-09       Impact factor: 5.887

5.  Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder.

Authors:  Mohammad Obaidi; Elliot Offman; John Messina; Jennifer Carothers; Per G Djupesland; Ramy A Mahmoud
Journal:  Headache       Date:  2013-08-28       Impact factor: 5.887

Review 6.  Rescue therapies for seizure clusters: Pharmacology and target of treatments.

Authors:  Barry Gidal; Kamil Detyniecki
Journal:  Epilepsia       Date:  2022-09       Impact factor: 6.740

7.  Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review.

Authors:  Per Gisle Djupesland
Journal:  Drug Deliv Transl Res       Date:  2012-10-18       Impact factor: 4.617

8.  Theory-based analysis of clinical efficacy of triptans using receptor occupancy.

Authors:  Kentaro Tokuoka; Risa Takayanagi; Yuji Suzuki; Masayuki Watanabe; Yasuhisa Kitagawa; Yasuhiko Yamada
Journal:  J Headache Pain       Date:  2014-12-08       Impact factor: 7.277

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.